Date: 2014-04-28
Type of information: Series B financing round
Company: Enterome Bioscience (France)
Investors: Seventure Partners (France), Lundbeckfond Ventures, Omnes Capital (France)
Amount: €10 million
Funding type: series B financing round
Planned used: The funds raised will be used by Enterome to undertake the R&D and business development activities needed to capitalize on its unique Metagenotyping® process, which is creating new industry standards in the quantitative and functional analysis of the gut microbiome in relation to health and disease. This cutting-edge technology platform will allow the Company to develop new disease management solutions including biomarkers, companion diagnostics and, in time, therapeutics, for inflammatory bowel and metabolic disorders, two important disease areas where the gut microbiome plays a key role. The financing will be used for further clinical developments and the launch of the Company’s first products.
Others: * On April 28, 2014, Seventure has announced that Enterome Bioscience has received one the inaugural investments from its new €120m Health for Life Capital fund, which was launched in December 2013. Enterome, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, received a total of €5m from Seventure in its €10m Series B, €2.3m of which came from the Health for Life Capital fund. Seventure provided start-up and seed capital to Enterome and led its €10m Series A funding round in 2012. The funding has also been led by Lundbeckfond Ventures, and is supported by Omnes Capital. The company was established in 2012 in Paris, France, and has raised a total of €17.5m from leading venture capital investors (Seventure, Omnes Capital & Lundbeckfond Ventures) and two strategic investors (Danone & Shire).
Therapeutic area: Digestive diseases - Inflammatory diseases - Metabolic diseases
